Scientists at The New York Stem Cell Foundation (NYSCF) Research Institute are one step closer to creating a viable cell replacement therapy for multiple sclerosis from a patient’s own cells.
For the first time, NYSCF scientists generated induced pluripotent stem (iPS) cells lines from skin samples of patients with primary progressive multiple sclerosis and further, they developed an accelerated protocol to induce these stem cells into becoming oligodendrocytes, the myelin-forming cells of the central nervous system implicated in multiple sclerosis and many other diseases.
Existing protocols for producing oligodendrocytes had taken almost half a year to produce, limiting the ability of researchers to conduct their research. This study has cut that time approximately in half, making the ability to utilize these cells in research much more feasible.
Stem cell lines and oligodendrocytes allow researchers to “turn back the clock” and observe how multiple sclerosis develops and progresses, potentially revealing the onset of the disease at a cellular level long before any symptoms are displayed. The improved protocol for deriving oligodendrocyte cells will also provide a platform for disease modeling, drug screening, and for replacing the damaged cells in the brain with healthy cells generated using this method.
“We are so close to finding new treatments and even cures for MS. The enhanced ability to derive the cells implicated in the disease will undoubtedly accelerate research for MS and many other diseases,” said Susan L. Solomon, NYSCF Chief Executive Officer.
The Latest on: Cell replacement therapy
[google_news title=”” keyword=”Cell replacement therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cell replacement therapy
- Seattle Children's launches BrainChild Bio to accelerate CAR T-cell therapies for children with brain tumorson December 5, 2023 at 4:01 am
Seattle Children's today announced the launch of BrainChild Bio, Inc. to accelerate the advancement of chimeric antigen receptor (CAR) T-cell therapies in Central Nervous System (CNS) tumors.
- Supercell Acquires Exclusive Licensing from Japanese Immunotherapy Leader for Advanced NK Cell Treatment Technologyon December 4, 2023 at 12:39 am
Dr. Hiroshi Terunuma, a distinguished international authority in cancer treatment based in Japan and a long-standing partner of Supercell, has successfully administered NK cell therapy in over 40,000 ...
- Cell & Gene Therapy Virtual Event Series 2024on December 3, 2023 at 2:37 am
Labroots and the Cell & Gene Therapy planning committee are pleased to announce the inaugural Cell & Gene Therapy Virtual Event Series, taking place on October 16th, 2024. The Cell & Gene Therapy ...
- Stem cell therapy could protect cognition in progressive MSon December 2, 2023 at 4:00 pm
Share on Pinterest Stem cell therapy could help halt the progression of cognitive impairment in multiple sclerosis. Image credit: TEK IMAGE/SCIENCE PHOTO LIBRARY/Getty Images. About 2.8 million ...
- The future of cell and gene therapy manufacturingon November 30, 2023 at 4:00 pm
The cell and gene therapy manufacturing sector will face challenges in scaling up as the field expands to cover more common conditions. Image credit: Getty Images/ JulieanneBirch The global ...
- Stem cells might help knee arthritis patients avoid surgeryon November 29, 2023 at 3:00 pm
Nearly half of all adults will develop arthritis of the knee in their lifetime but one day, stem cells could help patients avoid surgery.
- Stem cell transplants can be a safe treatment for knee osteoarthritis painon November 28, 2023 at 9:00 am
A recent meta-analysis has concluded that, according to all the studies reviewed, stem cell transplantation can be a safe and effective treatment for knee osteoarthritis pain.
- Androgen Replacement Therapy – 5 Key Insights for Better Healthon November 27, 2023 at 4:00 pm
Blood Cell Count: There’s a risk of polycythaemia ... to address any mental health concerns related to the condition or its treatment. Androgen Replacement Therapy offers a promising solution to those ...
- Enzyme therapy approved for rare genetic condition in babieson November 26, 2023 at 4:01 pm
A treatment for a rare genetic condition that usually kills babies before they turn one is to be made available in England in a first for the NHS. It is hoped the move will help save the lives of ...
- Opinion: CAR T-cell therapy delays jeopardize lives of Canadians with blood canceron November 22, 2023 at 5:27 am
Back to video Clinical trials and real world experiences alike have proven the remarkable potential of CAR T-cell therapy, demonstrating its ability not only to yield durable remissions but, in some ...
via Bing News